Keywords: Evolocumab; PCSK9-inhibitors; Endothelial function; Brachial artery vasoreactivity test;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Inhibidores de la PCK9; Evolocumab; Dislipidemia; Hipercolesterolemia familiar; Metas en el cLDL; PCK9 inhibitors; Evolocumab; Dyslipidemia; Familial hypercholesterolemia; LDLc goals;
Keywords: Hyperlipidemia; Children; Cardiovascular monitoring; Statins; Evolocumab;
Keywords: Monoclonal antibodies; Tocilizumab; Alirocumab; Evolocumab; Reticuloendothelial system; IL-6; PCSK9; Methotrexate; Simvastatin;
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
Keywords: PCSK9; LDL-C; Familial hypercholesterolemia; Evolocumab; Monoclonal antibody; Safety;
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
Keywords: PCSK9; Evolocumab; Alirocumab; Cardiovascular outcomes; Safety;
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer
Keywords: Mitotane; Adrenocortical carcinoma; ACC; Hypercholesterolemia; PCSK9 inhibitors; PCSK9; Evolocumab;
Proprotein Convertase Subtilisin Kexin 9 Inhibitors
Keywords: PCSK9; Monoclonal antibodies; Evolocumab; Alirocumab; LDL-C; Hypercholesterolemia; Cardiovascular disease; Proprotein convertase subtilisin kexin 9;
Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber
Keywords: ProproteÃna convertasa de subtilisina/kexina tipo 9; Inhibidores proproteÃna convertasa de subtilisina/kexina tipo 9; Evolocumab; Alirocumab; LipoproteÃna de baja densidad; Proprotein convertase subtilisin/kexin type 9; Proprotein convertase subtilisin
The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Keywords: ApoB/ApoA-I; Apolipoprotein B/Apolipoprotein A-I; ALT; Alanine aminotransferase; AST; Aspartate aminotransferase; CI; Confidence interval; CVD; Cardiovascular disease; CHD; Coronary heart disease; AMG 145; Evolocumab; Q2W; Every 2Â weeks; Q4W; Every 4Â we
PCSK9 Inhibitors Show Value for Patients and the US Health Care System
Keywords: alirocumab; cardiovascular disease; cholesterol; evolocumab; familial hypercholesterolemia; microsimulation; PCSK9;
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
Keywords: PCSK9 inhibitors; Evolocumab; Alirocumab; Dyslipidemia; Hypercholesterolemia; Familial hypercholesterolemia; Statin intolerance; Lipid treatment guidelines;
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Keywords: cardiovascular disease; cost-effectiveness; evolocumab; hypercholesterolemia; LDL-C; PCSK9 inhibitors;
The efficacy of anti-PCSK9 antibodies: Results from recent trials
Keywords: Alirocumab; Anti-PCSK9 antibodies; Cardiovasvular disease; Evolocumab; PCSK9;
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Keywords: PCSK9; Evolocumab; Alirocumab; LDL target; Lipid lowering therapy; Familial hypercholesterolemia;
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Keywords: Heterozygous familial hypercholesterolemia; Low-density lipoprotein cholesterol; Cardiovascular risk; PCSK9 inhibitors; Alirocumab; Evolocumab;
New lipid therapies: PCSK9 inhibitors
Keywords: LDL; LDL receptor; Atherothrombosis; Familial hyperlipidemia; Alirocumab; Evolocumab;
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
Keywords: Alirocumab; Evolocumab; Ischemic stroke; Lipid lowering; Hypercholesterolemia; PCSK9 inhibitors;
LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response
Keywords: Familial hypercholesterolemia; LDL apheresis; PCSK9 inhibition; Innate immunity; Complement; Inflammation; Evolocumab;
A review of PCSK9 inhibition and its effects beyond LDL receptors
Keywords: PCSK9; Alirocumab; Evolocumab; Dyslipidemia;
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Keywords: ALT; alanine transaminase; ASO; antisense oligonucleotide; apoB; apolipoprotein B; CVD; cardiovascular disease; EGF; epidermal growth factor; LDL-C; low-density lipoprotein cholesterol; MTP; microsomal triglyceride transfer protein; PCSK9; proprotein conv
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Keywords: PCSK9; Proprotein Convertase Subtilisin/Kexin type 9; Alirocumab; Evolocumab; Bococizumab;
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab
Keywords: evolocumab; ezetimibe; hypercholesterolemia; LDL-cholesterol; statin intolerance; CHD; coronary heart disease; CI; confidence interval; CK; creatine kinase; HDL-C; high-density lipoprotein cholesterol; LDL-C; low-density lipoprotein cholesterol; LDLR; low
Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Keywords: evolocumab; dyslipidemia; monotherapy; PCSK9Â inhibition; AE; adverse event(s); CV; cardiovascular; HDL-C; high-density lipoprotein cholesterol; LDL-C; low-density lipoprotein cholesterol; Lp(a); lipoprotein; PCSK9; proprotein convertase subtilisin/kexin
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials
Keywords: dyslipidemia; evolocumab; lipoprotein(a); PCSK9Â inhibition; CVD; cardiovascular disease; LDL; low-density lipoprotein; PCSK9; proprotein convertase subtilisin/kexin type 9; Q2W; every 2 weeks; Q4W; every 4 weeks; SC; subcutaneous; UC LDL-C; low-density l